Professor Simon Mallal

Director, Institute for Immunology & Infectious Diseases

About me

Dr. Mallal is a physician scientist who has championed research that has driven improvements in clinical practice in HIV and infectious diseases since the early years of the AIDS epidemic. His seminal contributions have included 1. the first studies on the recognition and management of immune restoration disease, 2. the early use of HIV cohort studies for both research and clinical practice with development of novel statistical methods, 3. the recognition and characterization of thymidine-analogue associated lipoatrophy and other mitochondrial toxicities, 4. the use of pharmacogenetic testing to prevent abacavir and other drug hypersensitivity syndromes and characterize the pathogenesis of these syndromes and 5. The use of population based host-pathogen genetic analyses to characterize pathogen adaptation to host alleles to facilitate pathogenesis studies, epitope discovery and immunogen design. He has been an investigator on over 40 clinical trials dating back to the first trials of zidovudine monotherapy and taken a leadership role in seminal pharmacogenetic studies such as the PREDICT-1 and SHAPE studies that were critical to provide the level 1a evidence required to drive routine pharmacogenetic through to the T4 stage of translation.

Teaching area

Medicine, Immunology

Research areas

1.        I established the early use of HIV cohort studies for both research and clinical practice with the development of novel statistical methods. I designed and implemented the first local area network to service the health sector in Australia and used this to set up the Western Australian HIV Cohort Study and associated clinical database. This database was used in a number of studies to identify associations between polymorphic genes and clinical diseases or outcomes. In particular, I studied the influence of MHC-encoded genes on susceptibility to systemic lupus erythematosus and the rate of progression of HIV infection. Such disease association studies have contributed to our understanding of disease pathogenesis and have been useful in predicting clinical outcomes and at times influenced our clinical management.

a.            Cameron PU, Mallal SA, French MA, Dawkins RL. Major histocompatibility complex genes influence the outcome of HIV infection. Ancestral haplotypes with C4 null alleles explain diverse HLA associations. Human Immunology 1990;29(4):282-295.  [PMID: 1981061].

b.            Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL. Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. Journal of Rheumatology 1991;18(9):1350-1358. [PMID: 1757937].

c.             Gillieatt SJ, Mallal SA, French MA, Dawkins RL. Epidemiology of late presentation of HIV infection in Western Australia. Medical Journal of Australia 1992;157(2):117-118.  [PMID: 1630373].

d.            Dore GJ, Hoy JF, Mallal SA, Li Y, Mijch AM, French MA, Cooper DA, Kaldor JM. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997;16(1):39-43. [PMID: 9377123].

 2.            I have had a long-standing interest in immune restoration disease in HIV infected patients, which I first reported in the early 1990s. Recognition of immune restoration disease is essential to avoid misinterpretation of such events as adverse effects or failure of antiretroviral therapy, which may result in inappropriate cessation of antiretroviral therapy. These findings have had practical importance in the developing world, with the introduction of antiretroviral therapy to large numbers of immunodeficient patients, many of whom have latent tuberculosis. I was actively involved in educational activities of health care workers in the developing world.

a.            French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992;6(11):1293-1297.  [PMID: 1472334].

b.            Mallal SA, James IR, French MA. Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS 1994;8(9):1263-1269.  [PMID: 7802978].

c.             Mallal S, Martinez OP, French MA, James IR, Dawkins RL. Severity and outcome of Pneumocystis carinii pneumonia (PCP) in patients of known and unknown HIV status. Journal of Acquired Immune Deficiency Syndromes 1994;7(2):148-153.  [PMID: 7905524].

d.            French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Medicine 2000;1(2):107-115.  [PMID: 11737333].

3.            The recognition and characterization of chronic toxicities associated with highly active anti-retroviral therapy (HAART). Slowly progressive, subcutaneous fat wasting was common and cosmetically evident in patients, which caused considerable psychological distress and had a major impact on the uptake and adherence to HAART regimens. This side effect was initially attributed to HIV protease inhibitors, but we helped to define the central role of nucleoside-analogue reverse transcriptase inhibitors in the pathogenesis of lipoatrophy via mitochondrial toxicity in the adipocyte.

a.            Mallal S, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14(10):1309-1316.  [PMID: 10930144].

b.            John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy 2001;6(1):9-20.  [PMID: 11417766].

c.             Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17(9):1329-1338.  [PMID: 12799554].

d.            Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal S. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antiviral Therapy 2003;8(4):323-331.  [PMID: 14518702].

4.            Immune-mediated drug hypersensitivities are a significant cause of morbidity and mortality, although it is difficult to predict which individuals were at risk of these reactions. We described a striking association between HLA-B*5701 and abacavir hypersensitivity and designed and organized clinical trials to demonstrate that HLA-B*5701 screening eliminates abacavir hypersensitivity. From 2002-2008, we were involved in taking HLA-B*5701 screening from discovery through to clinical implementation, providing a roadmap for translation of other phamacogenetic tests. We have identified the molecular basis of abacavir hypersensitivity, in which binding of abacavir to the peptide-binding groove of HLA-B*5701, results in altered peptide binding and activation of pre-existing cross-reactive memory CD8 T cells.

a.            Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 2002; 359(9308):727-732.  [PMID: 11888582].

b.            Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine 2008; 358(6):568-579.  [PMID: 18256392].

c.             Saag MS, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M. SHAPE Study Team.  High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clinical Infectious Diseases 2008;46(7):1111-1118.  [PMID: 18444831].

d.            Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira CAF, Yang L, Mei H, Shi L, Shabanowitz J, English AM, Wriston A, Lucas A, Phillips E, Mallal S, Grey HM, Sette A, Hunt DF, Buus S. Peters B. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences, 2012 Jun 19;109(25):9959-64. [PMID:  22645359] [PMCID: PMC3382472].

5.            Another major research interest is in the genetics of host-pathogen interactions at a population level. In 2002, we reported that HLA polymorphisms were a major determinant of the enormous diversity of HIV at both the individual and population level. At the time, there was debate as to the relative contribution of founder effects and viral phylogeny to HIV diversity, but we were able to demonstrate the dominant nature of HLA-B restricted- selection pressure in controlling HIV and that the transmission and accumulation of CTL escape variants drives the negative associations between HLA and HIV polymorphisms. We went on to champion the International HIV Adaptation Cohort, which combines data from over 1,500 HIV sequences to help formulate the best immunogens for an HIV vaccine.

a.            Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal S. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296(5572):1439-1443.  [PMID: 12029127]. 

b.            Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H,Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009 Apr 2;458(7238):641-5. [PMID: 19242411] [PMCID: PMC3148020].

c.             Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, Huang JC, Riadi G, Mallal S, Jojic N. Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol. 2011 Feb;85(3):1310-1321.  [PMID: 21084470] [PMCID: PMC3020499].

6.            Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung’u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.Nature medicine. 2016; 22(6):606-13. [PMID: 27183217 PMCID: PMC4899163].

Awards and grants

Honors

2014       Fellow of the American Association for the Advancement of Science (AAAS)

2013       Association of American Physicians (AAP)

2009       Finalist in the Western Australian Citizen of the Year Award

2008       Health Services Award, World AIDS Day Award by West Australian AIDS Council

2007       Nominated for the Australian of the Year Award by the Premier of Western Australia

2005       Premier’s Prize for Achievement in Science (Western Australia)

Grants

 

 

 

 

Events and speaking engagements

Translation of Personalized Medicine into Primary Care Globally: What can be learnt from HLA-B*5701 screening to prevent Abacavir hypersensitivity?  ID Grand Rounds, Nashville, USA, 2 February 2017.

Role of Heterologous Immunity in Transplant Rejection and Other Experiments of Man.  Division of Hematology/Oncology Hematology Grand Rounds, Vanderbilt University, Nashville, USA, 30 March, 2016.

T Cells Behaving Badly: Evolution to Population to Single Cells.  ID Grand Rounds, Vanderbilt University, Nashville, USA, 10 March 2016.

Putting together core technologies to your AdVANTAGE.  PMI Research Retreat, Vanderbilt University, Nashville, USA, 30 January 2016.

Personalised approaches to Immunology.  Advances in Personalised Medicine Workshop, Science on the Swan Convention.  Perth Western Australia, 20 April 2015.

Heterologous Immunity: Parallels between Transplant Rejection and Drug Hypersensitivity.  Renal Medicine Seminar, Vanderbilt University. Nashville, USA, 12 December 2014.

Personalised Immunology. 2013 Biomedical Scientific Advisory Board, Vanderbilt University, Nashville, USA, 6 December 2013.

Drug hypersensitivity: providing a roadmap for the investigation of heterologous immunity. Marshall Centre for Infectious Diseases Research & Training, University of Western Australia, Research Day.  Perth, Australia, 22 September 2014.

Mechanisms of drug hypersensitivity. 17th World Congress of Basic & Clinical Pharmacology.  Cape Town, South Africa, 13-18 July 2014.

Experiments of man that shine light on enigmatic immune disease. Immunology Seminar Royal Perth Hospital. Perth Western Australia, 7 July 2014.

Impact of herpes control on the immune system. EAACI Congress 2014.  Copenhagen, Denmark, 7–11 June 2014.

The Flexner Discovery Lecture Series: Personalized Immunology from Bench to Bedside. Vanderbilt University, Nashville, USA, 22 May 2014.

Heterologous immune responses and drug hypersensitivity.  6th Drug Hypersensitivity Meeting (DHM6).  Bern, Switzerland, 7-13 April 2014.

Heterologous Immunity: a new model of drug hypersensitivity. 8th International Congress on Cutaneous Adverse Drug Reactions. Taipei, Taiwan, 14-17 November 2013.

Prevention of HIV in 2023: treatment as prevention, vaccines and cure. Can and will it be done? 16th Annual HIV Symposium, Nashville, USA, 1 November 2013.

Personalized Medicine: Unmet Needs and Opportunities. Clinical Pharmacology Fellows Conference, Division of Clinical Pharmacology, Vanderbilt University, Nashville, USA, 3 December 2013.

Role of Heterologous Immune Responses in Drug Hypersensitivity, Transplant Rejection, Infection and Autoimmunity, Medicine Grand Rounds, Vanderbilt University, Nashville, USA,  15 August 2013.

A roadmap for Translating Omics to improved clinical care and fundamental scientific insights.  Omics Australasia Symposium. Fremantle, Western Australia, 26-28 November 2012.

Abacavir and the altered peptide repertoire model: clinical implications. 11th HIV Congress. Glasgow, UK, 11-15 November 2012.

Making a difference in HIV patient’s life: What the Guidelines don’t tell you.  Asia-Pacific HIV Lecture series. Taiwan, 2-3 November 2012.

Long Term treatment considerations amongst the backbone HAART options and Making a difference in HIV patient’s life.  Asia-Pacific HIV Lecture series.  Taiwan, November 2 & 3, 2012.

Contemporary Approaches to ART: Individualising Therapy & Avoiding Long Term Toxicity.  Asia-Pacific HIV Lecture series. Guangzhou, China 26 October 26 & Shanghai October 27 2012.

What influence when life-long treatments start?  Quality of survival: seeking a way to find balance between efficiency and long term complication.  Asia-Pacific HIV Lecture series. Seoul, South Korea, October 23 2012.

Beyond Salvage Therapy.  HIV Expert Opinion Panel, Kuala Lumpur, Malaysia, October 20, 2012.

Collaboration and Culture.  SMHS Research Strategy Consultation, Fremantle, Western Australia.  18 October 2012.

Potential role of heterologous immunity in experiments of man and nature.  Vanderbilt University Medical Center.  Nashville, USA, 21 August 2012.

The paradigm shift in understanding of drug hypersensitivity: Implications for pre-clinical screening of compounds.  MRL Safety Group, West Point, NY, USA. 2012.

PK Consideration in Treatment.  HIV Global Therapeutic Expert Forum. Philadelphia, USA, 1-2 May 2012.

Potential role of heterologous immunity in experiments of man and nature. Department of Immunology, University of Toronto, Canada, 7 February 2012. 

Organizer: Translational Pharmacogenetics: Pharmacogenomics of HIV/Antiretroviral Therapy at Institute for Immunology and Infectious Diseases.  Satellite workshop in conjunction with ASCEPT conference. Perth, Western Australia, 4 December 2011.

Clinical Impact of Raltegravir new data 2011.  Raltegravir Expert Meeting. Tokyo, Japan, 2 October 2011.

Are the best ART regimens for induction the best regimes for maintenance?  Merck Satellite meeting ASHM.  Canberra, Australia, 27 September 2011.

Lipoatrophy: forgotten but never forgiving.  Body Positive New Zealand, HIV Treatment Updates.  Auckland, New Zealand, 26 August 2011.

Evolution of HIV Therapy.  Body Positive New Zealand, HIV Treatment Updates.  Auckland, New Zealand, 26 August 2011.

Potential role of Heterologous Immunity in drug hypersensitivity. UWA School of Pathology & Laboratory Medicine.  Perth, Western Australia, 17 June 2011.

Role of Heterologous Immunity in Transplantation Rejection and Drug Hypersensitivity.  Merck Sharp & Dohme, West Point.  West Point, USA, 6 May 2011.

Co-evolution of HLA and viruses. British Columbia Centre for Excellence in HIV/AIDS.  Forefront Lecture. Vancouver, Canada, 4 March 2011.

Organizer: The Evolution of HIV Care over the last three decades. Train the trainer. HIV Clinical Leaders from Asia-Pacific region at the Institute for Immunology and Infectious Diseases. Perth, Western Australia, 19-20 January 2011.

Translation of Personalized Medicine into the Clinic: Difficult but not Impossible.  Univation.  Perth, Western Australia, 4 November 2010.

Co-evolution of HLA and viruses. Marshall Centre, UWA.  Perth, Western Australia, 29 October 2010.

Translation of Personalized Medicine into the Clinic: Difficult but not Impossible.  Seminar presentation.  Sir Charles Gairdner Hospital.  Perth, Western Australia, 27 October 2010.

Pharmacogenomics and adverse reactions.  16th World Congress of Basic and Clinical Pharmacology.  Copenhagen, Denmark, 17-23 July 2010.

Drivers of Excellence in Clinical Care.  Leadership Western Australia.  Perth, Western Australia, 16 June 2010. 

Further Insights into the Genetic Predisposition to Abacavir Hypersensitivity.  The 4th International Drug Hypersensitivity Meeting. Rome, Italy, 22-25 April 2010.

Pharmacogenetics of Abacavir Hypersensitivity: What Might We Learn About Altered Self and Clinical Translation?  John Curtin Medical School, Australian National University, Canberra, Australia, 30 October 2009.

HIV, now a chronic disease.  ANZICS/ACCCN Intensive Care ASM meeting. Perth, Western Australia, 29 October 2009.

EBV and MS; Lessons from Hepatitis and HIV.  Multiple Sclerosis Research Australia meeting.  Sydney, Australia, 16 October 2009.

Drug Therapy in HIV Infection.   Merck Sharpe & Dohme Satellite meeting Annual Conference of the Australasian Society for HIV Medicine.  Brisbane, Australia, 9-11 September 2009.

Pharmacogenetic testing for predicting at risk patients.  Genotyping and flow cytometry of HLA-B.  AACC Conference.  Chicago, USA, 22 July 2009.

HLA-B*5701 screening for abacavir hypersensitivity: Immunopathogenesis and Laboratory implementation.  Pharmacogenetics workshop for the Russian Central Scientific Epidemiology Institute.   Moscow, Russia, 23 June 2009.

New Perspectives in Personalised Medicine: 25 Years of HIV Treatment.  HIV and Cardiovascular Disease: Implications for HIV Treatment. Moscow, Russia, 22 June 2009.

Pharmacogenetic Testing in HIV Therapy.  Genes for Health Conference, Fremantle, Western Australia, 4-6 May 2009.

Genetics of HIV.  Pathology Update 2009 (in conjunction with XXV WASPaLM) World Congress.  Sydney, Australia, 13-15 March 2009.

Co-evolution of HLA and viruses: implications and applications.  Australasian Society for Immunology Meeting. Canberra, Australia, 7-11 December 2008.

Co-evolution of viruses and their human host: what it might teach us?  Perth Immunology Group meeting. Perth, Australia, 9-10 October 2008.

Futuristic Forum for Personalized Infectious Disease Medicine.  Futuristic Forum for Personalized Infectious Disease Medicine. Chapel Hill, North Carolina, USA, 9 September 2008.

How might understanding of the co-evolution of HLA and viruses inform contemporary clinical issues?  20th Annual Australasian Society for HIV Medicine Conference Perth, Western Australia. 17-20 September 2008.

Clinical Applications of Pharmacogenetics in HIV.  Clinical Applications of Pharmacogenetics in HIV Symposium.  Isla Verde, Puerto Rico, 7 September 2008.

Viral Escape and Polymorphism: How could they contribute to Vaccine Development? Utrecht University.  The Netherlands, 15 April 2008.

Lipoatrophy and Long-term implications:  AIDS Care Rounds, St. Paul’s Hospital, British Columbia Centre for Excellence in HIV/AIDS.  Vancouver, Canada, 3 April 2008.

Metabolic co-morbidities of ART.  Medscape video interview.  15th Annual Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, 3-6 February 2008.

Immunogenetics of Abacavir Hypersensitivity: Immunopathogenesis and Laboratory Implementation of Screening for HLA-B*5701.  HIV Karolinska Forum, Nobel Forum. Stockholm Sweden, 20 November 2007.

The Debate for HLA-B*5701 screening to prevent abacavir hypersensitivity.  Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 20 September 2007.

Bringing personalized medicine to the HIV clinic: The HLA-B*5701 Story. Immunopathogenesis and Implementation. St. Vincent’s Hospital, Cornell University. New York, USA, HIV Grand Rounds. 11 September 2007 & Washington University, HIV Grand Rounds. 10 September 2007.

HLA-B*5701 and abacavir: and update:  Immunopathogenesis and Laboratory Aspects. GSK Canadian National Advisory Board. Toronto, Canada, 9 September 2007.

HIV Immunogen Design: What should and shouldn’t be included in a Clade B vaccine? ImmunoRio2007: 13th International Conference of Immunology. Rio de Janeiro, 21-25 August 2007.

HIV Adaptation to HLA Restricted Immune Responses:  Implications for Immunogen Design. ImmunoRio2007: 13th International Conference of Immunology. Rio de Janeiro, Brazil, 21-25 August 2007.

Presentation from the PREDICT-1 Study.  Pharmacogenetics Advisory Board. Sydney, Australia, 26 July 2007, GSK International Advisory Board. Sydney, Australia, 21 July 2007.

Clinical Applications of Pharmacogenetics: Immunopathogenesis and Laboratory Implementation. Satellite Symposia.  16th Annual Canadian Conference on HIV/AIDS Research. 27 April 2007.

Pharmacogenetics/genomics. 2nd A.C.H.I.L.L.E.S Advanced Course in HIV Illness. 19-21 April 2007.

Genomic mechanisms and metabolic complications, 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, USA, 26 February 2007.

Prediction of immunologically mediated abacavir hypersensitivity reaction:  HLA-B*5701 testing.  Epzicom, United States GSK National Advisory Board.  Santa Monica, USA, 24 February 2007.

Workshop:  Mitochondrial Toxicity – Academic Medical Centre. Amsterdam, The Netherlands, 24 January 2007.

HIV and HCV Adaptation to Treatment and Polymorphic Host Responses.  Dormont International Conference – Host-Pathogen Interactions in Chronic Infection. Bordeaux, France, 7-9 December 2006.

Drug hypersensitivity in the setting of HIV: pathogenesis and management. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 12-16 November 2006.

HIV and HCV Adaptation to Polymorphic Host Responses.  European Society for Clinical Virology/Society for General Microbiology Meeting.  Birmingham, UK, 3-6 September 2006.

HCV and HIV Adaptation to Polymorphic Host Defences: Parallels and Differences.  13th International Meeting on Hepatitis C Virus and Related Viruses (Molecular Virology & Pathogenesis). Cairns, Australia, 27-31 August 2006.

Pharmacogenetics and Clinical Characteristics of Patch-test Confirmed Patients with Abacavir Hypersensitivity.  7th International Workshop on Clinical Pharmacology of HIV Therapy.  Lisbon, Portugal, 20-22 April 2006.

Investigation of Deoxythymidylate Kinase Genetic Variation and its Influence on Haematological Response to Zidovudine Treatment.  Lisbon PK Meeting and abstract 7th International Workshop on Clinical Pharmacology of HIV Therapy.  Lisbon, Portugal, April 20-22, 2006.

Predisposition to Drug Hypersensitivity in Patients with HIV.  2nd International Drug Hypersensitivity Conference.   Liverpool, UK, 20 April 2006.

Plenary: Drugs & Genes: Pharmacogenetics and HIV Therapy.  12th Annual Conference of the British HIV Association.  Brighton, UK, 1 April 2006.

Abacavir HSR: Clinical and Laboratory Experience with HLA-B 5701* Screening.  PREDICT-1 Study (CNA106030) Monitors and Investigators Meeting PREDICT-1.  Paris, France, 28 March 2006.

Plenary: Genetics of the Immune Response: HIV as a Probe of HLA-Restricted Immune Responses.  Conjoint Scientific Meeting of the 35th Australasian Society for Immunology (ASI) and the 24th International HLA & Immunogenetics Workshop.  Melbourne, Australia, 4-8 December 2005.

Long term tolerability of NRTI combinations. McFarlane Burnett Centre, Melbourne, Australia, 1 December 2005.

Long-term tolerability of NRTI combinations.  GSK Australia Kivexa Launch, Sydney, Australia, 25-26 November 2005.

GSK Symposium: Safeguarding the Future: Pharmacogenomics and the short and long term tolerability of abacavir/lamivudine.  10th European AIDS Conference (EACS). Dublin, 19 November 2005.

Abacavir Hypersensitivity: Towards Diagnostic Precision and Preventive Screening. GSK Symposium, British HIV Association.   London, UK, 14-15 October 2005.

Symposium GSK: Impact des Associations de Nuc sur la Tolérance des Trithérapies dans le Temps.  Long-term tolerability of NRTI combinations.  Juan-Les-Pins, France, 13 October 2005.

Organizer and Chair Vaccine Roundtable: HIV Immunogen Design: Exploiting HLA Diversity.  AIDS Vaccine Conference 2005. Montreal, Canada, 6-9 September 2005.

Current Issues Symposium: Mitochondrial Toxicity Induced by Antiretroviral Nucleoside Analog Drugs.  International Conference on Environmental Mutagens (9th ICEM) and the 36th Annual Meeting of the Environmental Mutagen Society (EMS). San Francisco, USA, 4 September 2005.

Understanding HIV Pathogenesis and Treatment.  17th Annual Conference of the Australasian Society for HIV Medicine.  Hobart, Australia, 24-27 August 2005.

Role of adaptive immunity and viral evolution in vaccine design: Immune selection of viral variants.  3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 26 July 2005.

Abacavir and Nevirapine Hypersensitivity: Genetics and Pathogenesis.  German and Austrian AIDS Congress 2005.  Vienna, Austria, 1 June 2005.

Kivexa: Long-Term Safety and Tolerability.  GSK Kivexa Launch.  Paris, France, May 2005.

Role of NRTI-induced adipocyte mtDNA depletion in lipoatrophy.  1st Meeting on Mitochondrial Toxicity and HIV Infection: Understanding the Pathogenesis for a Therapeutic Approach.  Modena, Italy, 19-21 May 2005.

Genomic Mechanisms of Metabolic Complications.  12th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, 22-25 February 2005. 

HIV adaptation to HLA restricted immune responses.  15th Challenge in Virology, Swiss Academic Foundation for Education in Infectious Diseases. Saanen, Switzerland, 14 January 2005.

HIV adaptation: Genetic hurdle, selective advantage and replicative cost.  Emerging Concepts in Antiretroviral Therapy. Center for AIDS Research, University of California, San Francisco, Gladstone Institute of Virology & Immunology, 12 January 2005.

HIV and HCV adaptation to HLA restricted responses.  St Paul’s Hospital, Vancouver, Canada, 10 January 2005.

Mitochondrial Genomes and Other Host Genes for Monitoring Antiretroviral Therapy (Including Pathogenesis of ART Induced Lipoatrophy).  AACC Meeting, San Francisco, USA, November 2004.

HIV and Hepatitis C Adaptation to HLA-Restricted Immune Responses. 2004 International Meeting of the Institute of Human Virology. Baltimore, USA, 31 October – 4  November 2004. 

Review of the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 2004.  ICAAC, Washington DC, USA.  October 2004.

Abacavir hypersensitivity as a model for elucidating Class I-restricted drug reactions.  GSK Canadian Advisory Board.  Montreal, Canada, 22 October 2004.

Human immunodeficiency virus and hepatitis C adaptation to HLA restricted immune responses.  16th Australian Society for HIV Medicine Conference. Canberra, Australia, 4 September 2004.

How can we apply understanding of host-pathogen genetic interactions to the search for an effective HIV vaccine?  Human Genetics Society of Australasia 28th Annual Scientific Meeting – Genes West, Fremantle, Western Australia.  11-13 August, 2004.

HIV adaptation to HLA restricted responses at an individual and population level.  Co-chair of Mini-Symposium: “HIV and Immunity”, HR05.5.  12th International Congress of Immunology and 4th Annual Conference of FOCIS.  Montreal, Canada, 23 July 2004.

HLA Imprinting: Implications for selection of vaccine immunogens.  Session 15, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 10 February 2004.

Vaccine Development: Can Host HLA Diversity be Exploited to Overcome the Problems of HIV Diversity? AIDS Vaccine 2003.   New York City, USA, 18-21 September 2003.

Understanding mitochondrial toxicity, prevention, monitoring and management.  43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 14-17 September 2003.

Symposium: The Future of Toxicogenomics in Antimicrobial Drug Development and Approval. The toxicogenomics of abacavir hypersensitivity. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 14-17 September 2003.

Hypersensitivity reactions to Ziagen. The GlaxoSmithKline HIV/AIDS Teleconference Series – Ziagen simply extending HIV treatment options.  28 June 2003.

HIV adaptation to HLA restricted immune responses. Annual Harvard Medical School Centers for AIDS Research Symposium.  Boston, USA, 16 June 2003.

Vaccine development – Can the problems of HIV and HLA diversity be overcome?  Workshop on Pathogen Genomics and Infectious Diseases in Africa.  Cape Town, South Africa, 1-22 March 2003.

How NRTIs and PIs may interact to cause the various manifestations of the lipodystrophy syndrome. The Australian Health and Medical Research Congress.  Melbourne, Australia, 25-29 November 2009.

HIV adaptation to HLA-restricted immune responses- implications for HIV vaccine design. The Australian Health and Medical Research Congress.  Melbourne, Australia, 25-29 November 2002.

Antiretroviral-induced mitochondrial toxicity, including hyperlactatemia and lactic acidosis.  6th International Congress on Drug Therapy in HIV Infections. Glasgow, UK, 17-21 November 2002.

Long-term complications of antiretroviral therapy.  HIV treatment 2002, management in the 3rd decade.  Phoenix, USA, 14-17 November 2002.

Lipodystrophy- insights from epidemiology and the laboratory. Australasian Society for HIV Medicine.  Sydney, Australia, 26 October 2002.

HIV mutational escape from CTL responses and antiretrovirals: parallels and differences.  2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 13-16 July 2002.

Therapeutic Challenges, Enhanced Clinical Expectations: Evolution of the Protease Inhibitor Class. “Managing Regimen Difficulties: Meeting the Challenge of Safety and Tolerability”. ACME Symposium at the 2nd IAS Conference on HIV Pathogenesis and Treatment.  Paris, France. 13-16 July 2002.

Understanding and managing the metabolic complications of anti-retroviral therapy, Cedars Sinai Hospital Grand Rounds. Los Angeles, USA, 30 April 2002.

Mitochondrial toxicity.  12th Clinical Care Options for HIV Symposium. Key Biscayne, Florida, USA, 27 April 2002.

Update on risk factors and management of lipodystrophy.  3rd European Workshop on Lipodystrophy.  Marbella, Spain, 25 April 2002.

Therapy for Life: Understanding and managing long-term antiretroviral toxicity: selected summary of the 3rd International Workshop of Adverse Drug Reactions and Lipodystrophy in HIV.  GSK Symposium: 8th European Conference on Clinical Aspects and Treatment of HIV Infection.  Athens, Greece, 27 October 2001.

Metabolic abnormalities and long-term side effects.  Nucleoside Expert Workshop.  Vienna, Austria, 19 June 2001.

Comparative long-term safety profiles of different first line option of treatment in HIV naïve patients.  XIth Symposium of HIV Infection. Toulon, France, 15 June 2001.

The role of antiretroviral therapy in the development of lipodystrophy.  HIV Treatment 2000: Clinical Management Issues. Tucson, USA, 30 November – 3 December 2000.  

Satellite Symposium: Resistance and HIV therapy: dogma, data and dilemma and therapy failure – resistance and other factors.  5th International Congress on Drug Therapy in HIV Infections.  Glasgow, UK, 22 October 2000.

Long-term toxicity of antiretroviral therapy.  Meet the Experts Session.  XIII International AIDS Conference.  Durban, South Africa, 9-14 July 2000.

What are the relative contributions of NRTIs and protease inhibitors to lipodystrophy?  4th International Conference on Nutrition and HIV infection, 2nd European Workshop on Lipodystrophy.  Cannes, France, 19-21 April 2000.

Metabolic complications of ART: clinical manifestations.  Glaxo Wellcome HIV Speakers Program 2000. New Orleans, USA, 14-15 April 2002.

Long-term complications: An Interactive Webcast.  Dr H Kessler, Dr W Powderly, Dr SA Mallal.  14 March 2000. 

Disorders of fat distribution in patients on anti-retroviral therapy. Australasian Society for HIV Medicine. Perth, Western Australia, 9-11 December 1999.

Ethical and scientific dilemmas in drug research and clinical trials. Plenary Session.  The Proceedings of the Australasian Pharmaceutical Science Association Annual Conference. Fremantle, Western Australia, 28 November – 1 December 1999.

HIV management – the passage into the millennium.  The future: Is there hope?  Satellite Symposium. Kuala Lumpur, Malaysia, 1 December 1998.

Needlestick injury.  The combined scientific meeting of the Australian and New Zealand College of Anaesthetists and the Australian Society of Anaesthetists.  Hyatt Hotel, Perth, Western Australia, 27 October 1996.

Ophthalmology and HIV disease.  28th Annual Scientists Conference of the Royal College of Ophthalmologists.  Perth, Western Australia, 1996.

How to estimate the efficacy of treatment on survival an immunological perspective. Maximising the utility of HIV patient observation databases.  Amsterdam, The Netherlands, 24 August 1996.

HIV infection: the host- immunogenetics and natural history.  The 38th Annual Scientific Meeting of the Royal Australasian College of Pathologists of Australasia. Perth, Western Australia, 29 September 1993.

Immunogenetics of HIV disease progression.  4th Asia-Oceanic International Histocompatibility Conference.  Perth, Western Australia, April 1993.

Cutaneous manifestations of HIV infection.  Australasian College of Dermatologists 26th Annual Meeting.  Perth, Western Australia, 3-8 May 1992.

Professional and community service

Professional services

Intramural

2015-                     Search Committee for Division Director, Paediatric Infectious Diseases.

2013-2014            Search Committee for Director, Vanderbilt Genetics Institute at Vanderbilt University.

2012                      Search Committee for Faculty positions, School of Psychology and Exercise Science, Murdoch University.

2004-2006              Private and public fundraising for, planning and establishment of the Institute for Immunology and Infectious Diseases at Murdoch University Website  http://iiid.murdoch.edu.au/

Video: http://www.youtube.com/watch?v=sSDq5egPVZU

2002                       Member, Royal Perth Hospital Genetics Advisory Committee.

1995-2010              Member, Royal Perth Hospital Postgraduate Education Committee.

1995-2001              Member, Royal Perth Hospital Ethics Committee.

 Extramural

2015                       Member, Organising Committee, 7th International Drug Hypersensitivity Meeting (DMH7), Malaga, Spain.

 2014                      Member, Organising Committee, 6th International Drug Hypersensitivity Meeting (DMH6), Switzerland.

 2014                      Member, Scientific Committee, HIV Drug Therapy Glasgow meeting, U.K.

2013-present          Member, Research Advisory Council, South Metropolitan Integrated Research Centre (SMIRdC), Western Australia.

March 2013            International expert advisor at NIAID/NIH-sponsored workshop on drug allergy.

 2012-present         Member, State Health Research Advisory Council (SHRAC), Western Australia.

 2012                      Member, Scientific Committee of 5th International Drug Hypersensitivity Meeting.

 2012                      Member, Australian National Health and Medical Research Council Immunology Project Grant Review Panel.

 2012                      Member, Conference Committee, International Drug Hypersensitivity Meeting (DHM5), Germany.

 2009-present         Member, Scientific Committee of International Congress on Drug Therapy in HIV Infection, U.K.

 2009-2012            Western Australian Institutes of Medical Research Governing Committee.

 2009                      Viiv Healthcare International HIV Advisory Board.

 2009                      Member, Argos Therapeutics HIV Advisory Board.

 2009                      Session Chair, 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, South Africa.

 2008                      Panel Chair, International Congress on Drug Therapy in HIV Infection, U.K.

 2007-2010            Member, Western Australian Sexual Health Advisory Committee.

 2007                      Johnson and Johnson International HIV Advisory Committee, Sydney.

 2007                      Member, Australian National Health and Medical Research Council Program Review Committee.

 2007                      Session Chair, 13th Annual Conference on Retroviruses and Opportunistic Infections, USA.

 2007                      Panel Chair, Interscience Conference on Antimicrobial Agents and Chemotherapy: Satellite Symposia, USA.

 2007                      Session Chair, 4th International AIDS Society Meeting (IAS 2007), Australia.

 2005                      Panel Chair, AIDS Vaccine 2005 International Conference, Canada.

 2005                      Member, Scientific Committee of International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Dublin, Ireland.

 2003-2006            External International Advisor for NIH Contract NIH contract N01-Al-15422, HLA typing and CTL epitope mapping to guide HIV vaccine development in China, Thailand, Peru and the USA.

 2003-2005            Merck International HIV Advisory Board.

 2002-2008            GSK International HIV Advisory Boards.

1989-present          Founding Member and Board Member, Immunodeficiency Foundation.

 Ad hoc Reviewer       

AIDS

Antiviral Therapy

Clinical Infectious Diseases (CID)              

Genome Medicine

Clinical & Experimental Immunology

Genome Medicine

JAMA

Journal of Acquired Immune Deficiency Syndromes (JAIDS)

Journal of NeuroVirology             

Journal of Virology (JVI)

Microbiology Australia

Nature Immunology

Pharmacogenetics and Genomics

PLOS Pathogens

Proceedings of the National Academy of Sciences (PNAS)

Science

The Journal of Clinical Investigations (JCI)

The Lancet

The Medical Letter

The Pharmacogenomics Journal

Canadian and European Drug Regulatory Authorities (independent reviews on abacavir hypersensitivity)

Major grant applications for US, Canadian, Dutch, Spanish and British granting agencies

 Community service

  • Actively involved, since the mid-80s, in informing both the general and gay community about HIV related issues, speaking at public meetings in country and city centers to provide education about the mode of transmission of HIV and treatment and care issues. 
  • Founded the Immunodeficiency Foundation in the late 80s, with nursing and paramedical staff, to raise money for HIV treatments and care and more recently to support HIV related research.  The Foundation has been instrumental in raising community awareness of HIV related treatment and care issues and the benefits of research both to HIV infected patients and the broader community.

 

Doctoral and masters supervisions

White, Katie (2014-present): Vanderbilt University Medical Center Postdoctoral Trainee; Co-mentor. Project title: Investigation of heterologous immunity model for drug hypersensitivity.

Rive, Craig, BSc Hon (2011 Honors; Mentor) (2012-present): Murdoch University PhD Student; Mentor. Project title: Immunopathogenesis of drug hypersensitivity.

Lucas, Andrew, PhD (2003-2014): Murdoch University Postdoctoral Trainee; Mentor. Project Title: Characterisation of T-cell responses in drug hypersensitivity. 

John, Mina, MBBS (2009-present): Murdoch University PhD Student; Mentor.     Project title: Adaptive interactions between HIV-1, antiretroviral therapy and human leukocyte antigens.

Herrmann, Susan, RN, MSc (2010-2013): Murdoch University PhD completed; Mentor. Project Title: By virtue of circumstance: HIV/AIDS in mobile and rural populations in Western Australia, an ethnographic study.

Nolan, David, MBBS (2008-2011): Murdoch University PhD completed; Mentor. Project Title: Factors Influencing the Toxicity and Efficacy of Antiretroviral Therapy For HIV Infection.

Pavlos, Rebecca, PhD (2008-present): Murdoch University Postdoctoral Trainee; Mentor. Project Title:Characterisation of T-cell responses in drug hypersensitivity.

Pfafferott, Katja, PhD (2006-2012): Postdoctoral Trainee; Mentor.  Project Title: Adaptation of Hepatitis C to host HLA-restricted immune responses in Australian populations.

 Pace, Craig, BSc (2001-2006): Murdoch University PhD and Postdoctoral training completed; Mentor.  Project Title: The Influence of Host Genetics on HIV Infection and Response to Antiretroviral Therapy.

Lucas, Michaela, MD, PhD (2004-present): Postdoctoral and Clinical Trainee; Mentor. Project Title:Characterisation of T-cell responses in drug hypersensitivity.

Tschochner, Monika, PhD (2008-present): Murdoch University Postdoctoral Trainee; Mentor. Project Title: Interaction between environment and genes on the prevalence, pathogenesis and phenotypes of MS in Western Australia.

Keane, Niamh, PhD (2008-present): Murdoch University Postdoctoral Trainee; Mentor. The influence of HIV on T cell function and application to vaccine design.

Hammond, Emma, PhD (2003-present): Postdoctoral Trainee; Mentor. Project Title:RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research.

Bronke, Corine, PhD (2009-2012): Postdoctoral Trainee; Mentor. Project Title: Interactions between adaptable pathogens drugs and the human host.

Almeida, Coral-Ann, PhD (2003-2007): Murdoch University PhD completed; Mentor.  Project Title: Characterisation of susceptibility to abacavir hypersensitivity carried on the HLA-*5701, -DRB1*0701 and –DQ3 haplotype.

Publications

Chapters

  • John, M., Gaudieri, S., Mallal, S., (2016),Immunogenetics and Vaccination,In: Human Vaccines: Emerging Technologies in Design and Development, Unknown, pages to.
  • Phillips, E., Mallal, S., (2011),Abacavir,In: Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory, Springer, pages 201 to 212.
  • Nolan, D., Mallal, S., Reiss, P., (2008),Complications Resulting from Antiretroviral Therapy for HIV Infection,In: Global HIV/AIDS Medicine, Saunders Elsevier, pages 181 to 191.

Journals

  • Karnes, J., Bastarache, L., Shaffer, C., Gaudieri, S., Xu, Y., Glazer, A., Mosley, J., Zhao, S., Raychaudhuri, S., Mallal, S., Ye, Z., Mayer, J., Brilliant, M., Hebbring, S., Roden, D., Phillips, E., Denny, J., (2017), Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants, Science Translational Medicine, 9, 389, .
  • Lindestam Arlehamn, C., Copin, R., Leary, S., Mack, S., Phillips, E., Mallal, S., Sette, A., Blatner, G., Siefers, H., Ernst, J., (2017), Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya, Human Immunology, 78, 4, .
  • Angelo, M., Grifoni, A., O'Rourke, P., Sidney, J., Paul, S., Peters, B., De Silva, A., Phillips, E., Mallal, S., Diehl, S., Kirkpatrick, B., Whitehead, S., Durbin, A., Sette, A., Weiskopf, D., (2017), Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity, Journal of Virology, 91, 5, .
  • Karnes, J., Shaffer, C., Bastarache, L., Gaudieri, S., Glazer, A., Steiner, H., Mosley, J., Mallal, S., Denny, J., Phillips, E., Roden, D., (2017), Comparison of HLA allelic imputation programs, PLoS One, 12, 2, .
  • Symons, J., Chopra, A., Malantinkova, E., Malantinkova, E., Leary, S., Cooper, D., Abana, C., Rhodes, A., Rezaei, S., Vandekerckhove, L., Mallal, S., Lewin, S., Cameron, P., (2017), HIV integration sites in latently infected cell lines: evidence of ongoing replication, Retrovirology, 14, 1, .
  • da Silva Antunes, R., Paul, S., Sidney, J., Weiskopf, D., Dan, J., Phillips, E., Mallal, S., Crotty, S., Sette, A., Lindestam Arlehamn, C., (2017), Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses, PLoS One, 12, 1, .
  • Pavlos, R., McKinnon, E., Ostrov, D., Peters, B., Buus, S., Koelle, D., Chopra, A., Schutte, R., Rive, C., Redwood, A., Restrepo, S., Bracey, A., Kaever, T., Myers, P., Speers, E., Malaker, S., Shabanowitz, J., Jing, Y., Gaudieri, S., Hunt, D., Carrington, M., Haas, D., Mallal, S., Phillips, E., (2017), Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles, Scientific Reports, 7, 1, .
  • Karnes, J., Shaffer, C., Cronin, R., Bastarache, L., Gaudieri, S., James, I., Pavlos, R., Steiner, H., Mosley, J., Mallal, S., Denny, J., Phillips, E., Roden, D., (2017), Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT), Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, doi: 10.1002/phar.1983. [Epub ahead of print]., , .
  • Sulzer, D., Alcalay, R., Garretti, F., Cote, L., Kanter, E., Agin-Lieves, J., Liong, C., McMurtrey, C., Hildebrand, W., Mao, X., Dawson, V., Dawson, T., Oseroff, C., Pham, J., Sidney, J., Dillon, M., Carpenter, C., Weiskopf, D., Phillips, E., Mallal, S., Peters, B., Frazier, A., Lindestam Arlehamn, C., Sette, A., (2017), T cells from patients with Parkinson's disease recognize -synuclein peptides, Nature: international weekly journal of science, 546, 7660, .
  • Hemler, J., Phillips, E., Mallal, S., Kendall, P., (2016), The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy, Annals Of Allergy Asthma & Immunology, 115, 6, pages 471 - 476.
  • Gitschlag, B., Kirby, C., Samuels, D., Gangula, R., Mallal, S., Patel, M., (2016), Homeostatic Responses Regulate Selfish Mitochondrial Genome Dynamics in C. elegans, Cell Metabolism, 24, 1, pages 91 - 103.
  • Carlson, J., Du, V., Pfeifer, N., Bansal, A., Tan, V., Power, K., Brumme, C., Kreimer, A., DeZiel, C., Fusi, N., Schaefer, M., Brockman, M., Gilmour, J., Price, M., Kilembe, W., John, M., Haubrich, R., Mallal, S., (2016), Impact of pre-adapted HIV transmission, Nature Medicine, 22, 6, pages 606 - 613.
  • Weiskopf, D., Angelo, M., Grifoni, A., O'Rourke, P., Sidney, J., Paul, S., De Silva, A., Phillips, E., Mallal, S., Premawansa, S., Premawansa, G., Wijewickrama, A., Peters, B., Sette, A., (2016), HLA DRB1 alleles are associated with different response magnitudes of dengue virus specific CD4+ T cell responses, Journal of infectious diseases, 214, 7, pages 1117 - 1124.
  • Magaret, A., Dong, L., John, M., Mallal, S., James, I., Warren, T., Gaudieri, S., Koelle, D., Wald, A., (2016), HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions, Genes and Immunity, 17, 7, pages -.
  • Loh, J., Gaddy, J., Algood, H., Gaudieri, S., Mallal, S., Cover, T., (2016), Helicobacter pylori adaptation in vivo in response to a high salt diet, Infection and Immunity, 83, 12, pages 4871 - 4883.
  • Cromer, D., Schlub, T., Smyth, R., Grimm, A., Chopra, A., Mallal, S., Davenport, M., Mak, J., (2016), HIV-1 Mutation and Recombination Rates Are Different in Microphages and T-Cells, Viruses, 8, 18, pages -.
  • Itani, H., Xiao, L., Saleh, M., Wu, J., Pilkinton, M., Dale, B., Barbaro, N., Foss, J., Kirabo, A., Montaniel, K., Norlander, A., Chen, W., Sato, R., Navar, L., Mallal, S., Madhur, M., Bernstein, K., Harrison, D., (2016), CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli, Circulation Research, 118, 8, pages 1233 - 1243.
  • Konvinse, K., White, K., Pavlos, R., Redwood, A., Trubiano, J., Ergen, E., Mallal, S., Phillips, E., (2016), Characterizing immune responses in severe T-cell mediated adverse drug reaction, Journal of Immunology, 196, 191:24, pages -.
  • Zhou, W., Toki, S., Zhang, J., Goleniewska, K., Newcomb, D., Cephus, J., Dulek, D., Bloodworth, M., Stier, M., Polosuhkin, V., Gangula, R., Mallal, S., Broide, D., Peebles, R., (2016), Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses, American Journal of Respiratory and Critical Care Medicine, 193, 1, pages 31 - 42.
  • Barnard, R., Chopra, A., James, I., Blinco, J., Watson, M., Jabara, C., Hazuda, D., Lemon, S., Mallal, S., Gaudieri, S., (2016), Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening, Antiviral Therapy, 21, 7, pages -.
  • Pham, J., Oseroff, C., Hinz, D., Sidney, J., Paul, S., Greenbaum, J., Vita, R., Phillips, E., Mallal, S., Peters, B., Sette, A., (2016), Sequence conservation predicts T cell reactivity against ragweed allergens, Clinical and Experimental Allergy, 46, 9, pages 1194 - 1205.
  • Jing, L., Laing, K., Dong, L., Russell, R., Barlow, R., Haas, J., Ramchandani, M., Johnston, C., Buus, S., Redwood, A., White, K., Mallal, S., Phillips, E., Posavad, C., Wald, A., Koelle, D., (2016), Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses, Journal of Immunology, 196, 5, pages 2205 - 2218.
  • Loi, S., Dushyanthen, S., Beavis, P., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D., Giltnane, J., Estrada, M., Sanchez, V., Sanders, M., Cook, R., Pilkington, M., Mallal, S., Wang, K., Miller, V., Stephens, P., Yelensky, R., Doimi, F., Gomez, H., Ryzhov, S., Darcy, P., Arteaga, C., Balko, J., (2016), RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors, Clinical Cancer Research, 22, 6, pages 1499 - 1509.
  • Wheatley, L., Plaut, M., Schwaninger, J., Banerji, A., Castells, M., Finkelman, F., Gleich, G., Guttmann-Yassky, E., Mallal, S., Naisbitt, D., Ostrov, D., Phillips, E., Pilcher, W., Platts-Mills, T., Roujeau, J., Schwartz, L., Trepanier, L., (2015), Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy, Journal of Allergy and Clinical Immunology, 136, 2, pages 262 - 271.e2.
  • Pfafferott, K., Deshpande, P., McKinnon, E., Merani, S., Lucas, A., Heckerman, D., Mallal, S., John, M., Gaudieri, S., Lucas, M., (2015), Anti-Hepatitis C virus T-cell immunity in the context of multiple exposures to the virus, PLoS One, 10, 6, pages e0130420 -.
  • Waugh, C., Cromer, D., Grimm, A., Chopra, A., Mallal, S., Davenport, M., Mak, J., (2015), A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library, Virology Journal, 12, 1, pages 55 -.
  • Strock, S., Gaudieri, S., Mallal, S., Yu, C., Mitchell, D., Cogan, J., Mason, W., Crowe, D., Loyd, J., (2015), Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 - a case control study, BMC Infectious Diseases, 15, 1, pages 206 -.
  • McLaren, P., Coulonges, C., Bartha, I., Lenz, T., Deutsch, A., Bashirova, A., Buchbinder, S., Carrington, M., Cossarizza, A., Dalmau, J., De Luca, A., Goedert, J., Gurdasani, D., Haas, D., Herbeck, J., Johnson, E., Kirk, G., Lambotte, O., Luo, M., Mallal, S., van Manen, D., Martinez-Picado, J., Meyer, L., Miro, J., Mullins, J., Obel, N., Poli, G., Sandhu, M., Schuitemaker, H., Shea, P., Theodorou, I., Walker, B., Weintrob, A., Winkler, C., Wolinsky, S., Raychaudhuri, S., Goldstein, D., Telenti, A., de Bakker, P., Zagury, J., Fellay, J., (2015), Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load, National Academy of Sciences. Proceedings, 112, 47, pages 14658 - 14663.
  • White, K., Chung, W., Hung, S., Mallal, S., Phillips, E., (2015), Evolving models of the immunopathogenesis of T-cell mediated drug allergy: The role of host, pathogens, and drug response, Journal of Allergy and Clinical Immunology, 136, 2, pages 219 - 234.
  • Pavlos, R., Mallal, S., Ostrov, D., Buus, S., Peters, B., Phillips, E., (2015), T Cell-Mediated Hypersensitivity Reactions to Drugs, Annual Review of Medicine, 66, , pages 439 - 454.
  • Metushi, I., Wriston, A., Banerjee, P., Gohlke, B., English, A., Lucas, A., Moore, C., Sidney, J., Buus, S., Ostrov, D., Mallal, S., Phillips, E., Shabanowitz, J., Hunt, D., Preissner, R., Peters, B., (2015), Acyclovir Has Low but Detectable Influence on HLA-B 57:01 Specificity without Inducing Hypersensitivity, PLoS One, 10, 5, pages e0124878 -.
  • Lucas, A., Lucas, M., Strhyn, A., Keane, N., McKinnon, E., Pavlos, R., Moran, E., Meyer-Pannwitt, V., Gaudieri, S., Kalams, S., Ostrov, D., Buus, S., Peters, B., Mallal, S., Phillips, E., (2015), Abacavir-Reactive Memory T Cells are present in Drug Nave Individuals, PLoS One, 10, 2, pages e0117160.doi:10.1371/journal.pone.0117160 -.
  • Payne, R., Branch, S., Kloverpris, H., Matthews, P., Koofhethile, C., Strong, T., Adland, E., Leitman, E., Frater, J., Ndung'u, T., Hunter, E., Haubrich, R., Mothe, B., Edwards, A., Riddell, L., Chen, F., Harrigan, R., Brumme, Z., Mallal, S., John, M., Jooste, P., Shapiro, R., Deeks, S., Walker, B., Brander, C., Landis, C., Carlson, J., Prado, J., Goulder, P., (2014), Differential escape patterns within the dominant HLA-b*57:03-restricted HIV gag epitope reflect distinct clade-specific functional constraints, Journal of Virology, 88, 9, pages 4668 - 4678.
  • Schlub, T., Grimm, A., Smyth, R., Cromer, D., Chopra, A., Mallal, S., Venturi, V., Waugh, C., Mak, J., Davenport, M., (2014), 15-20% of HIV substitution mutations are associated with recombination, Journal of Virology, 88, 7, pages 3837 - 3849.
  • Chikata, T., Carlson, J., Tamura, Y., Borghan, M., Naruto, T., Hashimoto, M., Murakoshi, H., Le, A., Mallal, S., John, M., Gatanaga, H., Oka, S., Brumme, Z., Takiguchi, M., (2014), Host-specific adaptation of HIV-1 subtype B in the Japanese population, Journal of Virology, 88, 9, pages 4764 - 4774.
  • Pavlos, R., Mallal, S., Ostrov, D., Ostrov, Y., Phillips, E., (2014), Fever, rash, and systemic symptoms: Understanding the role of virus and HLA in severe cutaneous drug allergy, Journal of Allergy and Clinical Immunology, 2, 1, pages 21 - 33.
  • Keane, N., Pavlos, R., McKinnon, E., Lucas, A., Rive, C., Blyth, C., Dunn, D., Lucas, M., Mallal, S., Phillips, E., (2014), HLA Class I restricted CD8+ and Class II restricted CD4 + T cells are implicated in the pathogenesis of nevirapine hypersensitivity, AIDS, 28, 13, pages 1891 - 1901.
  • Smyth, R., Schlub, T., Grimm, A., Waugh, C., Ellenberg, P., Chopra, A., Mallal, S., Cromer, D., Mak, J., Davenport, M., (2014), Identifying recombination hot spots in the HIV-1 genome, Journal of Virology, 88, 5, pages 2891 - 2902.
  • Rodriquez-Sainz, C., Valor, L., Hernandez, D., Gil, J., Carbone, J., Pascual-Bernaldez, M., Rodriquez-Alcantara, F., Martinez, I., Vicario, J., Mallal, S., Fernandez-Cruz, E., (2013), Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients, HIV Clinical Trials, 14, 4, pages 160 - 164.
  • Apps, R., Qi, Y., Carlson, J., Chen, H., Gao, X., Thomas, R., Yuki, Y., Del Prete, G., Goulder, P., Brumme, Z., Brumme, C., John, M., Mallal, S., (2013), Influence of HLA-C expression level on HIV control, Science, 340, 6128, pages 87 - 91.
  • Li, H., Blair, L., Chen, Y., Learn, G., Pfafferott, K., John, M., Bhattacharya, T., Hahn, B., Mallal, S., Shaw, G., Bar, K., (2013), Molecular Mechanisms of HIV Type 1 Prophylaxis Failure Revealed by Single-Genome Sequencing, Journal of infectious diseases, 208, 10, pages 1598 - 1603.
  • Herrmann, S., McKinnon, E., Hyland, N., Lalanne, C., Mallal, S., Nolan, D., Chassany, O., Duracinsky, M., (2013), HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection, Health and Quality of Life Outcomes, 11, 1, pages 1186 - 1477.
  • Bronke, C., Almeida, C., McKinnon, E., Roberts, S., Keane, N., Chopra, A., Carlson, J., Heckerman, D., Mallal, S., John, M., (2013), HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes, AIDS, 27, 6, pages 899 - 905.
  • Hertz, T., Oshansky, C., Roddam, P., DeVincenzo, J., Caniza, M., Jojic, N., Mallal, S., Phillips, E., James, I., Halloran, M., Thomas, P., Corey, L., (2013), HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection, National Academy of Sciences. Proceedings, 110, 33, pages 13492 - 13497.
  • Yagita, Y., Kuse, N., Kuroki, K., Gatanaga, H., Carlson, J., Chikata, T., Brumme, Z., Murakoshi, H., Akahoshi, T., Pfeifer, N., Mallal, S., John, M., Ose, T., Matsubara, H., Kanda, R., Fukunaga, Y., Honda, K., Kawashima, Y., Ariumi, Y., Oka, S., Maenaka, K., Takiguchi, M., (2013), Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity, Journal of Virology, 87, 4, pages 2253 - 2263.
  • McLaren, P., Coulonges, C., Ripke, S., van den Berg, L., Buchbinder, S., Carrington, M., Cossarizza, A., Dalmau, J., Geeks, S., Delaneau, O., De Luca, A., Goedert, J., Haas, D., Herbeck, J., Kathiresan, S., Kirk, G., Lambotte, O., Luo, M., Mallal, S., van Manen, D., (2013), Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls, PLoS Pathogens (Print), 9, 7, pages e1003515 -.
  • Herrmann, S., McKinnon, E., Williams, L., John, M., Mallal, S., Lucas, M., Nolan, D., (2012), Use of alcohol, nicotine and other drugs in the Western Australian HIV Cohort study, Sexual Health: an interdisciplinary journal of sexual health including HIV/AIDS and sexually transmitted infections, 9, 2, pages 199 - 201.
  • Brockman, M., Chopera, D., Olvera, A., Brumme, C., Sela, J., Markle, T., Martin, E., Carlson, J., Le, A., McGovern, R., Cheung, P., Kelleher, A., Jessen, H., Markowitz, M., Rosenberg, E., Frahm, N., Sanchez, J., Mallal, S., John, M., Walker, B., (2012), Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity., Journal of Virology, 86, 12, pages 6913 - 6923.
  • Desmond, C., Gaudieri, S., James, I., Pfafferott, K., Chopra, A., Lau, G., Audsley, J., Day, C., Chivers, S., Gordon, A., Revill, P., Bowden, S., Ayres, A., Desmond, P., Thompson, A., Roberts, S., Locarnini, S., Mallal, S., Lewin, S., (2012), Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV)infection, and adaptation is greatest in HBV e Antigen-Negative Disease, Journal of Virology, 86, 2, pages 1181 - 1192.
  • Herrmann, S., Wardrop, J., John, M., Gaudieri, S., Lucas, M., Mallal, S., Nolan, D., (2012), The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: A qualitative report, Sexual Health: an interdisciplinary journal of sexual health including HIV/AIDS and sexually transmitted infections, 9, 5, pages 407 - 413.
  • Pavlos, R., Mallal, S., Phillips, E., (2012), HLA and pharmacogenetics of drug hypersensitivity., Pharmacogenomics, 13, 11, pages 1285 - 1306.
  • Ostrov, D., Grant, B., Pompeu, Y., Sidney, J., Harndahl, M., Southwood, S., Oseroff, C., Lu, S., Jakoncic, J., de Oliveira, C., Yang, L., Mei, H., Shi, L., Shabanowitz, J., English, A., Wriston, A., Lucas, A., Phillips, E., Mallal, S., Grey, H., Sette, A., Hunt, D., Buus, S., Peters, B., (2012), Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, National Academy of Sciences. Proceedings, , , pages -.
  • Carlson, J., Brumme, C., Martin, E., Listgarten, J., Brockman, M., Le, A., Chui, C., Cotton, L., Knapp, D., Riddler, S., Haubrich, R., Nelson, G., Pfeifer, N., DeZiel, C., Heckerman, D., Apps, R., Carrington, M., Mallal, S., Harrigan, R., John, M., Brumme, Z., (2012), Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV1., Journal of Virology, 86, 24, pages 13202 - 13216.
  • Hammond, E., McKinnon, E., Glendenning, P., Williams, R., Mallal, S., Phillips, E., (2012), Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV, Clinical Endocrinology, 76, 2, pages 201 - 206.
  • Keane, N., Roberts, S., Almeida, C., Krishnan, T., Chopra, A., Tulloch, E., Pavlos, R., Tschochner, M., Carlson, J., Mallal, S., Heckerman, D., James, I., John, M., (2012), High-avidity, high-IFN-producing CD8 T-cell responses following immune selection during HIV-1 infection, Immunology and Cell Biology, 90, 2, pages 224 - 234.
  • Pompeu, Y., Stewart, J., Mallal, S., Phillips, E., Peters, B., Ostrov, D., (2012), The structural basis of HLA-associated drug hypersensitivity syndromes, Immunological Reviews, 250, 1, pages 158 - 166.
  • Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Powell, E., Hellard, M., Riordan, S., Matthews, G., Sheridan, D., Nattermann, J., Smedile, A., Müller, T., Hammond, E., Dunn, D., Negro, F., Bochud, P., Mallal, S., Ahlenstiel, G., Stewart, G., George, J., Booth, D., (2011), IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: A cross-sectional study, PLoS Medicine (Print), 8, 9, pages -.
  • Pfafferott, K., Gaudieri, S., Ulsenheimer, A., James, I., Heeg, M., Nolan, D., John, M., Rauch, A., Mallal, S., Lucas, A., Klenerman, P., Diepolder, H., Lucas, M., (2011), Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity, PLoS One, 6, 2, pages -.
  • Almeida, C., Bronke, C., Roberts, S., McKinnon, E., Keane, N., Chopra, A., Kadie, C., Carlson, J., Haas, D., Riddler, S., Haubrich, R., Heckerman, D., Mallal, S., John, M., (2011), Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes, Journal of Immunology, 187, 5, pages 2502 - 2513.
  • Hertz, T., Nolan, D., James, I., John, M., Gaudieri, S., Phillips, E., Huang, J., Riadi, G., Mallal, S., Jojic, N., (2011), Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins, Journal of Virology, 85, 3, pages 1310 - 1321.
  • Dong, T., Zhang, Y., Xu, K., Yan, H., James, I., Peng, Y., Blais, M., Gaudieri, S., Chen, X., Lun, W., Wu, H., Qu, W., Rostron, T., Li, N., Mao, Y., Mallal, S., Xu, X., McMichael, A., John, M., Rowland-Jones, S., (2011), Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China, Blood, 118, 1, pages 98 - 106.
  • Kostenko, L., Kjer-Nielsen, L., Nicholson, I., Hudson, F., Lucas, A., Foley, B., Chen, K., Lynch, K., Nguyen, J., Wu, A., Tait, B., Holdsworth, R., Mallal, S., Rossjohn, J., Bharadwaj, M., McCluskey, J., (2011), Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity, Tissue Antigens: immune response genetics, 78, 1, pages 11 - 20.
  • Phillips, E., Chung, W., Mockenhaupt, M., Roujeau, J., Mallal, S., (2011), Drug hypersensitivity: Pharmacogenetics and clinical syndromes, Journal of Allergy and Clinical Immunology, 127, 3, Supplement 1, pages S60 - S66.
  • Smyth, R., Schlub, T., Grimm, A., Venturi, V., Chopra, A., Mallal, S., Davenport, M., Mak, J., (2010), Reducing chimera formation during PCR amplification to ensure accurate genotyping, Gene, 469, 1-2, pages 45 - 51.
  • Phillips, E., Mallal, S., (2010), Pharmacogenetics of drug hypersensitivity, Pharmacogenomics, 11, 7, pages 973 - 987.
  • Iwabu, Y., Kinomoto, M., Tatsumi, M., Fujita, H., Shimura, M., Tanaka, Y., Ishizaka, Y., Nolan, D., Mallal, S., Sata, T., Tokunaga, K., (2010), Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes, Journal of Biological Chemistry, 285, 46, pages 35350 - 35358.
  • Almeida, C., Roberts, S., Pavlos, R., McKinnon, E., Ahmad, I., Keane, N., Chopra, A., Kadie, C., Heckerman, D., Mallal, S., John, M., (2010), Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses, Vaccine, 28, 37, pages 6052 - 6057.
  • John, M., Heckerman, D., James, I., Park, L., Carlson, J., Chopra, A., Gaudieri, S., Nolan, D., Haas, D., Riddler, S., Haubrich, R., Mallal, S., (2010), Adaptive interactions between HLA and HIV-1: Highly divergent selection imposed by HLA class I molecules with common supertype motifs, Journal of Immunology, 184, 8, pages 4368 - 4377.
  • Tschochner, M., Chopra, A., Maiden, T., Ahmad, I., James, I., Furrer, H., Gunthard, H., Mallal, S., Rauch, A., John, M., (2009), Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance, Antiviral Therapy, 14, 7, pages 953 - 964.
  • Brumme, Z., John, M., Carlson, J., Brumme, C., Chan, D., Brockman, M., Swenson, L., Tao, I., Szeto, S., Rosato, P., Sela, J., Kadie, C., Frahm, N., Brander, C., Haas, D., Riddler, S., Haubrich, R., Walker, B., Harrigan, P., Heckerman, D., Mallal, S., (2009), HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins, PLoS One, 4, 8, pages -.
  • Phillips, E., Mallal, S., (2009), Successful translation of pharmacogenetics into the clinic, Molecular Diagnosis & Therapy, 13, 1, pages 1 - 9.
  • Fellay, J., Ge, D., Shianna, K., Colombo, S., Ledergerber, B., Cirulli, E., Urban, T., Zhang, K., Zhang, K., Gumbs, C., Smith, J., Castagna, A., Cozzi-Lepri, A., De Luca, A., Easterbrook, P., Gunthard, H., Mallal, S., Mussini, C., Dalmau, J., Martinez-Picado, J., Martinez-Picado, J., Miro, J., Obel, N., Wolinsky, S., Martinson, J., Detels, R., Margolick, J., Jacobson, L., Descombes, P., Antonarakis, S., Beckmann, J., O'Brien, S., Letvin, N., McMichael, A., Haynes, B., Carrington, M., Carrington, M., Feng, S., Telenti, A., Goldstein, D., (2009), Common genetic variation and the control of HIV-1 in humans, PLoS Genetics (Print), 5, 12, pages e1000791 -.
  • Kawashima, Y., Pfafferott, K., Frater, J., Matthews, P., Payne, R., Addo, M., Gatanaga, H., Fujiwara, M., Hachiya, A., Koizumi, H., Kuse, N., Oka, S., Duda, A., Prendergast, A., Crawford, H., Leslie, A., Brumme, Z., Brumme, C., Allen, T., Brander, C., Kaslow, R., Tang, J., Hunter, E., Allen, S., Mulenga, J., Branch, S., Roach, T., John, M., Mallal, S., Ogwu, A., Shapiro, R., Prado, J., Fidler, S., Weber, J., Pybus, O., Klenerman, P., Ndung'u, T., Phillips, R., Heckerman, D., Harrigan, R., Walker, B., Takiguchi, M., Goulder, P., (2009), Adaptation of HIV-1 to human leukocyte antigen class I, Nature: international weekly journal of science, 458, 7238, pages 641 - 645.
  • Miura, T., Brumme, C., Brockman, M., Brumme, Z., Pereyra, F., Block, B., John, M., Mallal, S., Harrigan, R., Walker, B., (2009), HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers, Journal of Virology, 83, 7, pages 3407 - 3412.
  • Phillips, E., Mallal, S., (2009), HLA and drug-induced toxicity, CURRENT OPINION IN MOLECULAR THERAPEUTICS, 11, 3, pages 231 - 242.
  • Egger, S., Petoumenos, K., Kamarulzaman, A., Hoy, J., Sungkanuparph, S., Chuah, J., Falster, K., Zhou, J., Law, M., Nolan, D., Mallal, S., (2009), Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD), Journal of Acquired Immune Deficiency Syndromes, 50, 5, pages 513 - 520.
  • Rauch, A., Rauch, A., James, I., Pfafferott, K., Nolan, D., Klenerman, P., Cheng, W., Mollison, L., McCaughan, G., Shackel, N., Jeffrey, G., Baker, R., Freitas, E., Humphreys, I., Furrer, H., Gunthard, H., Hirschel, B., Mallal, S., John, M., Lucas, M., Barnes, E., Gaudieri, S., Gaudieri, S., (2009), Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure, Hepatology, 50, 4, pages 1017 - 1029.
  • Almeida, C., Roberts, S., Pavlos, R., McKinnon, E., Ahmad, I., Pfafferott, K., Keane, N., Lucas, A., Chopra, A., Mallal, S., Mallal, S., John, M., John, M., Turley, J., Rushton, B., (2009), Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses, Journal of Immunological Methods, 344, 1, pages 1 - 5.
  • Phillips, E., Mallal, S., (2009), Personalizing antiretroviral therapy: is it a reality, Personalized Medicine, 6, 4, pages 393 - 408.
  • Avila-Rios, S., Avila-Rios, S., Ormsby, C., Carlson, J., Valenzuela-Ponce, H., Blanco-Heredia, J., Garrido-Rodriguez, D., Garcia-Morales, C., Heckerman, D., Brumme, Z., Brumme, Z., Mallal, S., John, M., Espinosa, E., Reyes-Teran, G., (2009), Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study, Retrovirology, 6, , pages -.
  • Gaudieri, S., Gaudieri, S., Rauch, A., Rauch, A., Pfafferott, K., Barnes, E., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G., Mollison, L., Baker, R., Furrer, H., Gunthard, H., Freitas, E., Humphreys, I., Klenerman, P., Mallal, S., James, I., Roberts, S., Nolan, D., Lucas, M., Lucas, M., (2009), Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy, Hepatology, 49, 4, pages 1069 - 1082.
  • Chessman, D., Kostenko, L., Lethborg, T., Purcell, A., Williamson, N., Chen, Z., Kjer-Nielsen, L., Mifsud, N., Tait, B., Holdsworth, R., Almeida, C., Nolan, D., Macdonald, W., Archbold, J., Kellerher, A., Marriott, D., Mallal, S., Bharadwaj, M., Rossjohn, J., McCluskey, J., (2008), Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity, Immunity, 28, 6, pages 822 - 832.
  • Hammond, E., McKinnon, E., Mallal, S., Nolan, D., (2008), Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy, AIDS, 22, 18, pages 2540 - 2543.
  • Phillips, E., Mallal, S., (2008), Pharmacogenetics and the potential use for the individualization of antiretroviral therapy, Current Opinion in Infectious Diseases, 21, , pages 16 - 24.
  • Rauch, A., Rauch, A., Nolan, D., Thurnheer, C., Fux, C., Cavassini, M., Chave, J., Opravil, M., Phillips, E., Mallal, S., Furrer, H., (2008), Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study, Antiviral Therapy, 13, 8, pages 1019 - 1028.
  • Sabin, C., d'Arminio Monforte, A., Friis-Moller, N., Weber, R., El-Sadr, W., Reiss, P., Kirk, O., Mercie, P., Law, M., De Wit, S., Pradier, C., Phillips, A., Lundgren, J., Mallal, S., (2008), Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on mycardial infarction, Clinical Infectious Diseases, 46, 7 (Apr 1), pages 1101 - 1110.
  • Brumme, Z., Brumme, C., Carlson, J., Streeck, H., John, M., Eichbaum, Q., Block, B., Baker, B., Kadie, C., Markowitz, M., Jessen, H., Kellerher, A., Rosenberg, E., Kaldor, J., Yuki, Y., Carrington, M., Allen, T., Mallal, S., Altfeld, M., Heckerman, D., Walker, B., (2008), Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection, Journal of Virology, 82, 18 (Sep), pages 9216 - 9227.
  • Mallal, S., Phillips, E., Carosi, G., Molina, J., Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., Benbow, A., (2008), HLA-B*5701 screening for hypersensitivity to abacavir, The New England Journal of Medicine, 358, Feb 7, pages 568 - 579.
  • d'Arminio Monforte, A., Abrams, D., Pradier, C., Weber, R., Reiss, P., Bonnet, F., Kirk, O., Law, M., De Wit, S., Friis-Moller, N., Phillips, A., Sabin, C., Lundgren, J., Mallal, S., (2008), HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS defining malignancies, AIDS, 22, 16, pages 2143 - 2153.
  • Sabin, C., Worm, S., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., De Wit, S., Law, M., d'Arminio Monforte, A., Friis-Moller, N., Kirk, O., Pradier, C., Weller, I., Phillips, A., Lundgren, J., Mallal, S., (2008), Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, The Lancet, 371, 9622 (Apr 26), pages 1417 - 1426.
  • McKinnon, E., John, M., Mallal, S., Herrmann, S., Hyland, N., Martinez, P., Cain, A., Turner, K., Coombs, A., Manolikos, C., (2008), Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care, Internal Medicine Journal, 38, , pages 8 - 15.
  • Almeida, C., Martin, A., Nolan, D., Lucas, A., CAMERON, P., James, I., Phillips, E., Mallal, S., (2008), Cytokine profiling in abacavir hypersensitivity patients, Antiviral Therapy, 13, 2, pages 281 - 288.
  • Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., Hughes, A., Sutherland-Phillips, D., Mallal, S., Shaefer, M., (2008), High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clinical Infectious Diseases, 46, 1 Apirl, pages 1111 - 1118.
  • Rauch, A., Rauch, A., Nolan, D., Furrer, H., McKinnon, E., John, M., Mallal, S., Gaudieri, S., Gaudieri, S., Gunthard, H., Schmid, P., Battegay, M., Hirschel, B., Telenti, A., James, I., (2008), HLA-Bw4 homozygosity is associated with an impaired CD4 T Cell recovery after initiation of antiretroviral therapy, Clinical Infectious Diseases, 46, (June) 12, pages 1921 - 1925.
  • Hammond, E., Mamotte, C., Mallal, S., (2007), HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay, Tissue Antigens: immune response genetics, 70, , pages 58 - 61.
  • Phillips, E., Mallal, S., (2007), Drug hypersensitivity in HIV, Current Opinion in Allergy and Clinical Immunology, 7, 4, pages 324 - 330.
  • Hammond, E., Almeida, C., Mamotte, C., Nolan, D., Phillips, E., Schollaardt, T., Gill, M., Angel, J., Neurath, D., Li, J., Giulivi, T., McIntyre, C., Koultchitski, G., Wong, B., Reis, M., Rachlis, A., Cole, D., Choo, B., Neifer, S., Lalonde, R., Roger, M., Jeanneau, A., Mallal, S., (2007), External quality assessment of HLA-B*5701 reporting: An international multicentre survey, Antiviral Therapy, 12, 7, pages 1027 - 1032.
  • Fellay, J., Shianna, K., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., Cozzi-Lepri, A., De Luca, A., Easterbrook, P., Francioli, P., Mallal, S., Martinez-Picado, J., Miro, J., Obel, N., Smith, J., Wyniger, J., Descombes, P., Antonarakis, S., Letvin, N., McMichael, A., Haynes, B., Telenti, A., Goldstein, D., (2007), A whole-genome association study of major determinants for host control of HIV-1, Science, 317, 5840, pages 944 - 947.
  • Frahm, N., Yusim, K., Suscovich, T., Adams, S., Sidney, J., Hraber, P., Hewitt, H., Linde, C., Kavanagh, D., Woodberry, T., Henry, L., Faircloth, K., Listgarten, J., Kadie, C., Jojic, N., Sango, K., Brown, N., Pae, E., Zaman, M., Bihl, F., Kahtri, A., John, M., Mallal, S., Marincola, F., Walker, B., Sette, A., Heckerman, D., Korber, B., Brander, C., (2007), Extensive HLA class I allele promiscuity among viral CTL epitopes, European Journal of Immunology, 371, 9, pages 2419 - 2433.
  • Carlson, J., Kadie, C., Mallal, S., Heckerman, D., (2007), Leveraging hierarchical population structure in discrete association studies, PLoS One, 2, 7, pages 1 - 13.
  • Bhattacharya, T., Daniels, M., Heckerman, D., Foley, B., Frahm, N., Kadie, C., Carlson, J., Yusim, K., McMahon, B., Gaschen, B., Mallal, S., Mullins, J., Nickle, D., Herbeck, J., Rousseau, C., Learn, G., Miura, T., Brander, C., Walker, B., Korber, B., (2007), Founder effects in the assessment of HIV polymorphisms and HLA allele associations, Science, 315, 5818, pages 1583 - 1586.
  • Martin, A., Almeida, C., Cameron, P., Purcell, A., Nolan, D., James, I., McCluskey, J., Phillips, E., Landay, A., Mallal, S., (2007), Immune responses to abacavir in antigen-presenting cells from hypersensitive patients, AIDS, 21, , pages 1233 - 1244.
  • Harari, A., Cellerai, C., Enders, F., Kostler, J., Codarri, L., Tapia, G., Boyman, O., Castro, E., Gaudieri, S., James, I., John, M., Wagner, R., Mallal, S., Pantaleo, G., (2007), Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype, National Academy of Sciences. Proceedings, 104, 41, pages 16233 - 16238.
  • Gabutero, E., Moore, C., Mallal, S., Stewart, G., Williamson, P., (2007), Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS, AIDS, 21, , pages 65 - 69.
  • Frahm, N., Kiepiela, P., Adams, S., Linde, C., Hewitt, H., Sango, K., Feeney, M., Addo, M., Lichterfeld, M., Lahaie, M., Pae, E., Wurcel, A., Roach, T., St. John, M., Altfeld, M., Marincola, F., Moore, C., Mallal, S., Carrington, M., Heckerman, D., Allen, T., Mullins, J., Korber, B., Goulder, P., Walker, B., Brander, C., (2006), Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes, Nature Immunology, 7, 2, pages 173 - 178.
  • Gaudieri, S., Rauch, A., Park, L., Freitas, E., Herrmann, S., Jeffrey, G., Cheng, W., Pfafferott, K., Hahn, V., Chapman, R., Battegay, M., Weber, R., Telenti, A., Furrer, H., James, I., Lucas, M., Mallal, S., (2006), Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection, Journal of Virology, 80, 22, pages 11094 - 11104.
  • Pace, C., Keller, J., Nolan, D., James, I., Gaudieri, S., Moore, C., Mallal, S., (2006), Population level analysis of Human Immunodeficiency Virus Type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation, Journal of Virology, 80, 18, pages 9259 - 9269.
  • Martin, A., Krueger, R., Nolan, D., Phillips, E., Mallal, S., Almeida, C., (2006), A Sensitive and Rapid Alternative to HLA Typing as a Genetic Screening Test for Abacavir Hypersensitivity Syndrome, Pharmacogenetics and Genomics, 16, 5, pages 353 - 357.
  • Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., Mallal, S., (2006), Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study, Clinical Infectious Diseases, 43, 1, pages 99 - 102.
  • Bihl, F., Frahm, N., Di Giammarino, L., Sidney, J., John, M., Yusim, K., Woodberry, T., Sango, K., Hewitt, H., Henry, L., Linde, C., Chisholm III, J., Zaman, M., Pae, E., Mallal, S., Walker, B., Sette, A., Korber, B., Heckerman, D., Brander, C., (2006), Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses, Journal of Immunology, 176, 7, pages 4094 - 4101.
  • Cherry, C., Nolan, D., James, I., McKinnon, E., Mallal, S., Gahan, M., Lal, L., McArthur, J., Wesselingh, S., (2006), Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals, Journal of Acquired Immune Deficiency Syndromes, 42, 4, pages 435 - 440.
  • Martin, A., Nolan, D., Almeida, C., Rauch, A., Mallal, S., (2006), Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: From bedside to bench and back again, Pharmacogenomics, 7, 1, pages 15 - 23.
  • Nolan, D., Gaudieri, S., Mallal, S., (2006), Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system, Current Opinion in Immunology, 18, xx, pages 413 - 421.
  • Pett, S., Wand, H., Law, M., Arduino, R., Lopez, J., Knysz, B., Pereira, L., Pollack, S., Reiss, P., Tambussi, G., Abrams, D., Mallal, S., (2006), Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants, HIV Clinical Trials, 7, 2, pages 70 - 85.
  • Nolan, D., Reiss, P., Mallal, S., (2005), Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics, Expert Opinion on Drug Safety, 4, , pages 201 - 218.
  • Vidal, F., Vilades, C., Domingo, P., Broch, M., Pedrol, E., Dalmau, J., Knobel, H., Peraire, J., Gutierrez, C., Sambeat, M., Fontanet, A., Deig, E., Cairo, M., Montero, M., Richart, C., Mallal, S., (2005), Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele, Journal of Acquired Immune Deficiency Syndromes, 40, 5, pages 527 - 531.
  • Allen, T., Altfeld, M., Geer, S., Kalife, E., Moore, C., O'Sullivan, K., DeSouza, I., Feeney, M., Eldridge, M., Maier, E., Kaufmann, D., Lahaie, M., Reyor, L., Tanzi, G., Johnston, M., Brander, C., Draenert, R., Rockstroh, J., Jessen, H., Rosenberg, E., Mallal, S., Walker, B., (2005), Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution, Journal of Virology, 79, 21, pages 13239 - 13249.
  • Petoumenos, K., Ringland, C., Goodman, R., Gotowski, M., Couldwell, D., Lewis, L., Austin, D., Block, M., Quan, D., Gowers, A., Brown, K., Skobalj, N., Mallal, S., (2005), Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database, HIV Medicine, 6, 3, pages 155 - 163.
  • John, M., Moore, C., James, I., Mallal, S., (2005), Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1, Antiviral Therapy, 10, , pages 551 - 555.
  • Phillips, E., Wong, G., Kaul, R., Shahabi, K., Nolan, D., Knowles, S., Martin, A., Mallal, S., Shear, N., (2005), Clinical and immunologic correlates of abacavir hypersensitivity, AIDS, 19, , pages 979 - 987.
  • Martin, A., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., Phillips, E., Christiansen, F., Mallal, S., (2005), Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4+ T-cell counts, AIDS, 19, , pages 97 - 99.
  • Gaudieri, S., Nolan, D., McKinnon, E., Witt, C., Mallal, S., Christiansen, F., (2005), Associations between KIR epitope combinatons expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses, Molecular Immunology, 42, , pages 557 - 560.
  • Lucas, A., Gaudieri, S., Rauch, A., Nolan, D., Mallal, S., (2005), Cellular tropism of HIV-1 mediated and constrained by coreceptor dependencies, Journal of Viral Entry, 1, , pages 17 - 27.
  • Martin, A., Nolan, D., Mallal, S., (2005), HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing, Tissue Antigens: immune response genetics, 65, , pages 571 - 574.
  • Nolan, D., James, I., Mallal, S., (2005), HIV: Experiencing the pressures of modern life, Science, 307, , pages 1422 - 1424.
  • Allen, T., Yu, X., Kalife, E., Reyor, L., Lichterfeld, M., John, M., Cheng, M., Allgaier, R., Mui, S., Frahm, N., Alter, G., Brown, N., Johnston, M., Rosenberg, E., Mallal, S., Brander, C., Walker, B., Altfeld, M., (2005), De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection, Journal of Virology, 79, 20, pages 12952 - 12960.
  • Feeney, M., Tang, Y., Pfafferott, K., Roosevelt, K., Draenert, R., Trocha, A., Yu, X., Verrill, C., Allen, T., Moore, C., Mallal, S., Burchett, S., McIntosh, K., Pelton, S., St. John, M., Hazra, R., Klenerman, P., Altfeld, M., Goulder, P., (2005), HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response, Journal of Immunology, 174, 12, pages 7524 - 7530.
  • Gaudieri, S., DeSantis, D., McKinnon, E., Moore, C., Nolan, D., Witt, C., Mallal, S., Christiansen, F., (2005), Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression, Genes and Immunity, not given, , pages 1 - 8.
  • Klepiela, P., Leslie, A., Honeyborne, I., Ramduth, D., Thobakgale, C., Chetty, S., Rathnavalu, P., Moore, C., Pfafferott, K., Hilton, L., Zimbwa, P., Moore, S., Allen, T., Brander, C., Addo, M., Altfeld, M., James, I., Mallal, S., Bunce, M., Barber, L., Szinger, J., Day, C., Klenerman, P., Mullins, J., Korber, B., Coovadia, H., Walker, B., Goulder, P., (2004), Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA, Nature: international weekly journal of science, 432, 7018, pages 769 - 774.
  • Nolan, D., Gaudieri, S., John, M., Mallal, S., (2004), Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground, AIDS, 18, , pages 1231 - 1240.
  • Martin, A., Nolan, D., Gaudieri, S., Almeida, C., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F., Purcell, A., McClusky, J., Mallal, S., (2004), Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp-Hom variant, National Academy of Sciences. Proceedings, 101, , pages 4180 - 4185.
  • Hammond, E., Nolan, D., James, I., Metcalf, C., Mallal, S., (2004), Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy, AIDS, 18, 5, pages 815 - 827.
  • Martin, A., Nolan, D., Gaudieri, S., Phillips, E., Mallal, S., (2004), Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity, Pharmacogenomics, 5, 6, pages 643 - 655.
  • Allen, T., Altfeld, M., Yu, X., O'Sullivan, K., Lichterfeld, M., Le Gall, S., John, M., Mothe, B., Lee, P., Kalife, E., Cohen, D., Freedberg, K., Strick, D., Johnston, M., Sette, A., Rosenberg, E., Mallal, S., Goulder, P., Brander, C., Walker, B., (2004), Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection, Journal of Virology, 78, 13, pages 7069 - 7078.
  • Martin, A., Smith, D., Carr, A., Hoy, J., Chuah, J., Mallal, S., Law, M., Clements, M., Cooper, D., Macrae, K., James, R., Mijch, A., McCormack, C., Baker, D., McLeod, H., Kidd, J., McFarlane, R., Vale, R., Roth, N., Wood, H., Finlayson, R., Bodsworth, N., Wheatley, D., Austin, D., Bloch, M., Frater, A., Doong, N., Hudson, J., Anderson, J., Patching, J., Leung, J., Lee, W., Sharkey, T., Wand, H., (2004), Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study), HIV Clinical Trials, 5, 4, pages 192 - 200.
  • Nolan, D., Hammond, E., James, I., McKinnon, E., Mallal, S., (2003), Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population level to the cellular level., Antiviral Therapy, 8, , pages 141 - 150.
  • Nolan, D., Gaudieri, S., Mallal, S., (2003), Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity?, Journal of HIV therapy, 8, 2, pages 36 - 41.
  • Nolan, D., Moore, C., Castley, A., Sayer, D., Mamotte, C., John, M., James, I., Mallal, S., (2003), Tumour necrosis factor - alpha gene-238 G/A promoter polymorphism associated with more rapid onset of lipodystrophy., AIDS, 17, 1, pages 121 - 122.
  • Hammond, E., Sayer, D., Nolan, D., Walker, U., Ronde, A., Montaner, J., Cote, H., Gahan, M., Cherry, C., Wesselingh, S., Reiss, P., Mallal, S., (2003), Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study, Journal Of Clinical Virology, 27, 1, pages 97 - 110.
  • Miller, J., Carr, A., Emery, S., Law, M., Mallal, S., Baker, D., Smith, D., Kaldor, J., Cooper, D., (2003), HIV lipodystrophy: prevalence, severity and correlates of risk in Australia, HIV Medicine, 4, 3, pages 293 - 301.
  • McKinnon, E., James, I., John, M., Mallal, S., (2003), Viral load detectability profiles for HIV-infection., Statistics in Medicine, 22, , pages 385 - 396.
  • Nolan, D., Mallal, S., (2003), Thymidine analogue-sparing highly active antiretroviral therapy (HAART), Journal of HIV therapy, 8, 1, pages 1 - 5.
  • Lincoln, D., Petoumenos, K., Dore, G., Finlayson, R., Clemons, J., Ellis, D., Baker, D., Kidd, J., McFarlane, R., Law, M., Smith, D., Huffam, S., Savage, J., Morgan, S., Knibbs, P., Rogers, G., Ree, H., Magon, H., Sowden, D., Walker, A., Orth, D., Lister, G., Chuah, J., James, R., Fankhauser, W., Dickson, B., Bradford, D., Wilson, C., Fairley, K., Roth, N., Eu, B., Strecker, S., Russell, D., Wood, H., Maijch, A., Hoy, J., Pierce, A., McCormack, C., Watson, K., Anderson, J., Moore, R., McGovern, G., McNair, R., Medland, N., Daye, J., Mallal, S., (2003), HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy, HIV Medicine, 4, 3, pages 241 - 249.
  • Amin, J., Moore, A., Carr, A., French, M., Emery, S., Cooper, D., Kotsiou, G., Norrito, L., Dwyer, D., Packham, D., Fordham, M., Garsia, R., Baker, D., Doong, N., Quan, D., Beveridge, A., Genn, W., Quin, J., Mulholland, J., Sowden, D., Rawlinsen, M., Rebic, D., Street, A., De Graaf, B., Roney, J., Bryant, M., McCormack, C., Hoy, J., Shaw, D., Ferguson, W., Waddell, R., Papanaoum, K., French, M., Mallal, S., Scull, N., Todhunter, L., James, R., Foreman, E., (2003), Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Ozcombo 1 and 2, HIV Clinical Trials, 4, 4, pages 252 - 261.
  • Nolan, D., Watts, G., Herrmann, S., French, M., John, M., Mallal, S., (2003), Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?, Quarterly Journal of Medicine (QJM), 96, , pages 825 - 832.
  • Martin, A., Hammond, E., Nolan, D., Pace, C., Den, B., Taylor, L., Moore, H., Martinez, O., Christiansen, F., Mallal, S., (2003), Accumulation of mitochondrial DNA mutations in human immunodeficiency virus - infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors, American Journal of Human Genetics, 72, 3, pages 549 - 560.
  • Nolan, D., Hammond, E., Martin, A., Taylor, L., Herrmann, S., McKinnon, E., Metcalf, C., Latham, B., Mallal, S., (2003), Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy, AIDS, 17, , pages 1329 - 1338.
  • Pace, C., Martin, A., Hammond, E., Mamotte, C., Nolan, D., Mallal, S., (2003), Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients, Antiviral Therapy, 8, , pages 35 - 43.
  • Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., Christiansen, F., (2002), Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, The Lancet, 359, , pages 727 - 732.
  • Moore, C., John, M., James, I., Christiansen, F., Witt, C., Mallal, S., (2002), Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level, Science, 296, , pages 1439 - 1443.
  • John, M., Mallal, S., (2002), Hyperlactatemia syndromes in people with HIV infection, Current Opinion in Infectious Diseases, 15, , pages 23 - 29.
  • John, M., Nolan, D., Mallal, S., (2001), Antiretroviral therapy and the lipodystrophy syndrome, Antiviral Therapy, 6, , pages 9 - 20.
  • Nolan, D., Upton, R., McKinnon, E., John, M., James, I., Adler, B., Roff, G., Vasikaran, S., Mallal, S., (2001), Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir, AIDS, 15, , pages 1275 - 1280.
  • John, M., Moore, C., James, I., Nolan, D., Upton, R., McKinnon, E., Mallal, S., (2001), Chronic hyperlactatemia in HIV infected patients taking antiretroviral therapy, AIDS, 15, , pages 717 - 723.
  • Nolan, D., John, M., Mallal, S., (2001), Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis, Antiviral Therapy, 6, , pages 145 - 160.
  • Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., Doong, N., French, M., Smith, D., Cooper, D., (2001), HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study, Journal of Virology, 15, 14, pages 1811 - 1822.